Albemarle Extends Monthly Loss to 20.6% at $105.78 Ahead of Q3 Results
Question
Albemarle Extends Monthly Loss to 20.6% at $105.78 Ahead of Q3 Results
Direct answer
Spot lithium carbonate and hydroxide price pressure compresses realized refinery conversion spreads, driving Albemarle's 20.6% monthly equity decline. — bearish pressure on ALB via battery-grade lithium pricing pass-through to specialty chemical margins.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Albemarle Extends Monthly Loss to 20.6% at $105.78 Ahead of Q3 Results”, revision 1, evidence through 2026-10-01. https://marketontology.com/catalysts/2026-10-01/albemarle-extends-monthly-loss-to-20-6-at-105-78-ahead-of-q3-results-b72ca1
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ALB | ▼Bear | 1–4 weeks | battery-grade lithium pricing pass-through to specialty chemical margins | 59 |
Albemarle Extends Monthly Loss to 20.6% at $105.78 Ahead of Q3 Results
Spot lithium carbonate and hydroxide price pressure compresses realized refinery conversion spreads, driving Albemarle's 20.6% monthly equity decline. — bearish pressure on ALB via battery-grade lithium pricing pass-through to specialty chemical margins.
Albemarle declined 1.71% to $105.78 and has fallen 20.6% over the past month
- SourceAlbemarle declined 1.71% to $105.78 and has fallen 20.6% over the past month
- TransmissionSpot lithium carbonate and hydroxide price pressure compresses realized refinery conversion spreads, driving Albemarle's 20.6% monthly equity decline.
- SummaryAlbemarle fell 1.71% to $105.78, widening its 30-day drop to 20.6%. The decline outpaces the broader specialty chemicals sector's 8.47% monthly drop.
- ALBDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ALB closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ALB price vs. pre-event level
- ALB volume vs. 20-day average
- Futures curve shape
- Inventory data
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Albemarle (ALB) Registers a Bigger Fall Than the Market: Important Facts to Note · Zacks Investment Research · 2026-09-30
Related catalysts
- 2026-10-17Albemarle Falls 2.84% to $95.39 as Chemical Specialty Multiple Contracts Before Q3ALB
- 2026-10-17Albemarle Falls 2.84% to $95.39 as Chemical Specialty Multiple Contracts Before Q3ALB
- 2026-10-17Albemarle drops to $95.39 as 1-month loss reaches 14.66% ahead of Nov. 4 reportALB LIT
- 2026-10-17Albemarle drops to $95.39 as 1-month loss reaches 14.66% ahead of Nov. 4 reportALB LIT
- 2026-10-13Albemarle Falls 2.73% to $98.51 Despite Forecasted Q3 EPS SurgeALB
- 2026-10-13Albemarle Falls 13.8% in One Month as Rank Downgrade Tempers Q3 EPS OutlookALB SPY-1.08%
- 2026-10-13Albemarle Falls 2.73% to $98.51 Despite Forecasted Q3 EPS SurgeALB
- 2026-10-13Albemarle Falls 2.73% to $98.51 Despite Forecasted Q3 EPS SurgeALB CPER-1.95%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.